U.S. markets open in 4 hours 18 minutes
  • S&P Futures

    4,261.50
    +6.75 (+0.16%)
     
  • Dow Futures

    34,415.00
    +34.00 (+0.10%)
     
  • Nasdaq Futures

    14,146.75
    +22.00 (+0.16%)
     
  • Russell 2000 Futures

    2,324.90
    +1.30 (+0.06%)
     
  • Crude Oil

    71.02
    +0.14 (+0.20%)
     
  • Gold

    1,864.60
    -1.30 (-0.07%)
     
  • Silver

    27.73
    -0.31 (-1.12%)
     
  • EUR/USD

    1.2127
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.40
    +0.75 (+4.79%)
     
  • GBP/USD

    1.4078
    -0.0030 (-0.21%)
     
  • USD/JPY

    110.1180
    +0.0570 (+0.05%)
     
  • BTC-USD

    39,678.73
    -554.13 (-1.38%)
     
  • CMC Crypto 200

    995.82
    +26.98 (+2.78%)
     
  • FTSE 100

    7,169.04
    +22.36 (+0.31%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

Chairman & CEO Wei-Wu He Just Bought 4.7% More Shares In CASI Pharmaceuticals, Inc. (NASDAQ:CASI)

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
  • Oops!
    Something went wrong.
    Please try again later.

Potential CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders may wish to note that the Chairman & CEO, Wei-Wu He, recently bought US$488k worth of stock, paying US$2.15 for each share. Although the purchase only increased their holding by 4.7%, it is still a solid purchase in our view.

View our latest analysis for CASI Pharmaceuticals

CASI Pharmaceuticals Insider Transactions Over The Last Year

In fact, the recent purchase by Chairman & CEO Wei-Wu He was not their only acquisition of CASI Pharmaceuticals shares this year. They previously made an even bigger purchase of US$5.6m worth of shares at a price of US$1.90 per share. Even though the purchase was made at a significantly lower price than the recent price (US$2.58), we still think insider buying is a positive. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

In the last twelve months CASI Pharmaceuticals insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!

insider-trading-volume
insider-trading-volume

There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).

Insider Ownership

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. It appears that CASI Pharmaceuticals insiders own 9.6% of the company, worth about US$31m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At CASI Pharmaceuticals Tell Us?

The recent insider purchase is heartening. We also take confidence from the longer term picture of insider transactions. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. Insiders likely see value in CASI Pharmaceuticals shares, given these transactions (along with notable insider ownership of the company). In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing CASI Pharmaceuticals. Every company has risks, and we've spotted 3 warning signs for CASI Pharmaceuticals you should know about.

But note: CASI Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.